Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 5 May 1978:
Vol. 200. no. 4341, pp. 567 - 568
DOI: 10.1126/science.347574
Prev | Table of Contents | Next

Articles

Science, Vol 200, Issue 4341, 567-568
Copyright © 1978 by American Association for the Advancement of Science

articles

Schizophrenic symptoms improve with apomorphine

CA Tamminga, MH Schaffer, RC Smith, and JM Davis

Eighteen chronic schizophrenic patients received subcutaneous doses of apomorphine, a dopamine receptor agonist, and of placebo in separate trials. A significant improvement in psychotic symptoms occurred after apomorphine compared to placebo. The results are interpreted as a consequence of presynaptic dopamine receptor activation by apomorphine with a subsequent decrease in dopamine-mediated neural transmission.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder.
H. M. Abdolmaleky, K.-h. Cheng, S. V. Faraone, M. Wilcox, S. J. Glatt, F. Gao, C. L. Smith, R. Shafa, B. Aeali, J. Carnevale, et al. (2006)
Hum. Mol. Genet. 15, 3132-3145
   Abstract »    Full Text »    PDF »
Mechanism of New Antipsychotic Medications: Occupancy Is Not Just Antagonism.
G. Grunder, A. Carlsson, and D. F. Wong (2003)
Arch Gen Psychiatry 60, 974-977
   Abstract »    Full Text »    PDF »
Disrupted Pattern of D2 Dopamine Receptors in the Temporal Lobe in Schizophrenia: A Postmortem Study.
S. K. Goldsmith, R. M. Shapiro, and J. N. Joyce (1997)
Arch Gen Psychiatry 54, 649-658
   Abstract »    PDF »
Local and Distributed Effects of Apomorphine on Fronto-Temporal Function in Acute Unmedicated Schizophrenia.
P. C. Fletcher, C. D. Frith, P. M. Grasby, K. J. Friston, and R. J. Dolan (1996)
J. Neurosci. 16, 7055-7062
   Abstract »    Full Text »    PDF »
Dopamine Agonist Treatment of Schizophrenia With N-Propylnorapomorphine.
C. A. Tamminga, M. D. Gotts, G. K. Thaker, L. D. Alphs, and N. L. Foster (1986)
Arch Gen Psychiatry 43, 398-402
   Abstract »    PDF »
Apomorphine's Antipsychotic Activity.
M. H. Schaffer, J. M. Davis, and C. A. Tamminga (1985)
Arch Gen Psychiatry 42, 927
   Abstract »    PDF »
Apomorphine and Schizophrenia: Treatment, CSF, and Neuroendocrine Responses.
M. I. Levy, B. M. Davis, R. C. Mohs, K. S. Kendler, A. A. Mathe, G. Trigos, T. B. Horvath, and K. L. Davis (1984)
Arch Gen Psychiatry 41, 520-524
   Abstract »    PDF »
Long-term Pimozide Pretreatment Differentially Affects Behavioral Responses to Dextroamphetamine in Schizophrenia: Further Exploration of the Dopamine Hypothesis of Schizophrenia.
D. P. van Kammen, J. P. Docherty, S. R. Marder, J. N. Rayner, and W. E. Bunney Jr (1982)
Arch Gen Psychiatry 39, 275-281
   Abstract »    PDF »
Des-Tyrosine-{gamma}-Endorphin Administration in Chronic Schizophrenics: A Preliminary Report.
C. A. Tamminga, P. J. Tighe, T. N. Chase, E. G. DeFraites, and M. H. Schaffer (1981)
Arch Gen Psychiatry 38, 167-168
   Abstract »    PDF »
Neurochemical and behavioral evidence for a selective presynaptic dopamine receptor agonist.
D. Goodale, D. Rusterholz, J. Long, Flynn JR, B Walsh, J. Cannon, and T Lee (1980)
Science 210, 1141-1143
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)